<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03504449</url>
  </required_header>
  <id_info>
    <org_study_id>SCRM-01</org_study_id>
    <nct_id>NCT03504449</nct_id>
  </id_info>
  <brief_title>Surgery Without Neoadjuvant Chemoradiotherapy Compared With Neoadjuvant Chemoradiotherapy for Rectal Cancer With Negative Circumferential Resection Margin Based on MRI Assessment, a Perspective Multicenter Randomized Controlled Trial</brief_title>
  <acronym>SCRM-01</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Chao Yang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Chao Yang Hospital</source>
  <brief_summary>
    <textblock>
      For now, neoadjuvant chemoradiotherapy is routinely performed for T3N1-2M0 rectal cancer.&#xD;
      However, there are lots of complications following neoadjuvant chemoradiotherapy, such as&#xD;
      Wound-related complications, anastomotic leakage, anastomotic stenosis, sexual dysfunction,&#xD;
      testicular or ovary failure. Patients undergoing resection for rectal cancer had low rates of&#xD;
      local recurrence and long disease-free survival regardless of whether an APR, CAA or low AR&#xD;
      was performed. The main purpose of preoperative radiotherapy is to lower the local&#xD;
      recurrence. For the T3N1-2M0 rectal cancer with negative circumferential resection margin&#xD;
      based on MRI assessment, we suppose might not necessary to receive neoadjuvant&#xD;
      chemoradiotherapy, for operation can achieve the negative circumferential resection margin.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2016</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>circumferential resection margin</measure>
    <time_frame>one week after operation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>introperative perforation</measure>
    <time_frame>During the operation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>local recurrece</measure>
    <time_frame>3 years after operation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overal survival</measure>
    <time_frame>3 years after operation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>disease-free survival</measure>
    <time_frame>3 years after operation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>complications</measure>
    <time_frame>30 days after operation</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Circumferential Resection Margin</condition>
  <condition>Intraoperative Perforation of Rectum</condition>
  <condition>Local Recurrence of Malignant Tumor of Rectum</condition>
  <condition>Disease-free Survival</condition>
  <condition>Overal Survival</condition>
  <arm_group>
    <arm_group_label>surgery without neoadjuvant chemoradiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>For T3N1-2M0 rectal cancer with negative circumferential resection margin based on MRI assessment, recieve surgery without neoadjuvant chemoradiotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>surgery with neoadjuvant chemoradiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>For T3N1-2M0 rectal cancer with negative circumferential resection margin based on MRI assessment, recieve surgery following neoadjuvant chemoradiotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>neoadjuvant chemoradiotherapy</intervention_name>
    <arm_group_label>surgery with neoadjuvant chemoradiotherapy</arm_group_label>
    <arm_group_label>surgery without neoadjuvant chemoradiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Tumor within 12 cm of the anal verge&#xD;
&#xD;
          2. T3N1-2 as determined by preoperative MRI examination&#xD;
&#xD;
          3. negative circumferential resection margin determined by preoperative MRI examination&#xD;
&#xD;
          4. Absence of distant metastases&#xD;
&#xD;
          5. Absence of intestinal obstruction&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. With distant metastases&#xD;
&#xD;
          2. With intestinal obstruction&#xD;
&#xD;
          3. Pregnancy or lactation&#xD;
&#xD;
          4. With operation contraindication&#xD;
&#xD;
          5. With mental disorder&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jiagang Han, MD</last_name>
    <phone>+861085231604</phone>
    <email>wzhj611@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Chaoyang Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiagang Han, Professor</last_name>
      <phone>8613522867841</phone>
      <email>hjg211@163.com</email>
    </contact>
    <investigator>
      <last_name>Jiagang Han, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zhenjun Wang, professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Guanghui WEI, Professor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>April 12, 2018</study_first_submitted>
  <study_first_submitted_qc>April 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 20, 2018</study_first_posted>
  <last_update_submitted>February 4, 2021</last_update_submitted>
  <last_update_submitted_qc>February 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Chao Yang Hospital</investigator_affiliation>
    <investigator_full_name>Zhen Jun Wang</investigator_full_name>
    <investigator_title>Chairman of General Surgery</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

